A new study published in Therapeutic Innovation & Regulatory Science provides crucial insights into the design and ...
Phase 2 clinical trial will evaluate the safety, translational biology, and exploratory clinical efficacy of VYD2311 in people with Long COVID or COVID vaccine injuryParticipants to include people ...
The FDA approved external trigeminal nerve stimulation (TNS) in 2019 as the first non-drug device for treating ADHD, ...
The NCCN guidelines now include MammaPrint for identifying HR+/HER2- early-stage breast cancer patients who may benefit from ...
In today's healthcare environment, securing regulatory approval is only the beginning. The real challenge lies in ensuring ...
The DROP-FPF trial is the first Phase 3 trial in interstitial lung disease (ILD) to use automated, quantitative ...
RAPT Therapeutics, Inc. is being acquired by GSK plc for $2.2B as ozureprubart targets IgE disorders with 8–12 week dosing.
A recent study conducted in Norway suggests that MDMA-assisted therapy may provide lasting relief for individuals suffering from major depressive disorder. The findings indicate that the clinical ...
In head-to-head non-human primate (NHP) studies, average observed half-life of ASC37 was approximately 17 days, 7-fold longer than retatrutide, which supports once-monthly subcutaneous (SQ) dosing in ...
Korro Bio, Inc. ( KRRO) 44th Annual J.P. Morgan Healthcare Conference January 15, 2026 1:30 PM EST ...
New analysis details the national platforms, standards, and vendor landscape shaping EMR consolidation, interoperability, medicines safety, and cyber resilience across Aotearoa New Zealand DUNEDIN, NZ ...
Neurodegenerative diseases (NDDs) represent a profound challenge to global health, characterized by progressive neuronal dysfunction and loss, leading to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback